Skip to content

VR and Cooled Genicular Nerve Radio Frequency Ablation for Chronic Knee Pain

Can Virtual Reality Improve Patient Tolerance in Patients Undergoing Water Cooled Genicular Nerve Radio Frequency Ablation in Patients With Chronic Knee Pain? A Randomized Controlled Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06336447
Enrollment
62
Registered
2024-03-28
Start date
2024-01-12
Completion date
2027-02-28
Last updated
2024-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Chronic

Keywords

Pain, Knee Pain, Virtual Reality, Radio Frequency Ablation, Genicular Nerve Block

Brief summary

This study will examine the impact of virtual reality used in conjunction with sedation compared to sedation alone in patients undergoing watervcooled genicular nerve ablations for chronic knee pain. The goals of the study is to determine the relative efficacy of virtual reality as a distraction modality when used as an adjuvant to procedural sedation compared to sedation alone for procedure related pain. To assess procedural satisfaction, and 1-month pain and functional outcomes.To explore whether virtual reality and lower procedure-related pain scores affect 1-month outcomes. And finally to determine whether demographic and clinical characteristics are associated with outcome measures.

Interventions

OTHERExperimental: Group #1: Virtual Reality Headset

Group 1 will be assigned to the Virtual Realtity Headset. Participants will wear the device for at least 10 minutes prior to the planned procedure. Subjects will receive standard procedure. The VR Headset will be removed 10 minutes after the planned procedure.

OTHERGroup 2 No Virtual Reality Headset

Group 2 will receive standard care without the use of the Virtuality Reality Heaset.

Sponsors

Northwestern University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Outcome assessor will be blinded to study randomization

Intervention model description

Randomized controlled trail.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients undergoing genicular RFA will be eligible for inclusion in the study * Patients with knee pain, baseline average of \> 4/10 * X-ray evidence of osteoarthritis of the knee * Pain duration of \>6 weeks and no previous knee surgeries * Patients will also only be included who have never undergone a RFA on the affected knee

Exclusion criteria

* Individuals who do not have evidence of osteoarthritis on X-ray, * Secondary gain expected to influence treatment outcomes * Poorly controlled psychiatric condition that could affect outcome (e.g. active substance abuse) or impose a barrier to participation * Chronic opioid use and anticoagulation therapy that cannot be stopped and could warrant a different treatment approach (e.g. phenol ablation) * Severe motion sickness * Seizure disorder * Vision loss * Pregnant * Nursing

Design outcomes

Primary

MeasureTime frameDescription
Procedural related pain10 minutes after procedureReported procedural related pain on a 0-10 verbal rating scale (VRS)

Secondary

MeasureTime frameDescription
Procedure related satisfaction10 minutes after prodedureProcedure related satisfaction on a 1-5 Likert scale (5=most satisfied, 1=least satisfied)
Post procedure anxiety10 minutes after procedurePost-procedural numerical rating scale (NRS) for anxiety on an 11-point scale (0=no anxiety 10=worst possible level of anxiety)
Mean reduction in pain 1 month after procedure30 days after procedureMean reduction on a 0-10 numerical rating scale (NRS) pain scores for average and worst knee pain at 1 month
Midazolam administered10 minutes before procedure to end of prodedureMilligrams of midazolam administered during procedure for sedation
Fentanyl administered10 minutes before procedure to end of prodedureMicrograms of fentanyl administered during procedure

Countries

United States

Contacts

Primary ContactPaul Fitzgerald, RN,BSN,MS
p-fitzgerald2@northwestern.edu312-695-1064

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026